PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33647456-4	2021	We demonstrated that cyclophosphamide (Cy) pre-conditioning significantly modified the immunosuppressive TME and was required to uncover the efficacy of PSCA-CAR T cells in metastatic prostate and pancreas cancer models, with no observed toxicities in normal tissues with endogenous expression of PSCA.	Cyclophosphamide	21-37	prostate stem cell antigen	Mus musculus	153-157
33647456-4	2021	We demonstrated that cyclophosphamide (Cy) pre-conditioning significantly modified the immunosuppressive TME and was required to uncover the efficacy of PSCA-CAR T cells in metastatic prostate and pancreas cancer models, with no observed toxicities in normal tissues with endogenous expression of PSCA.	Cyclophosphamide	39-41	prostate stem cell antigen	Mus musculus	153-157
29602820-3	2018	Methods: We developed a dual-labeled probe based on A2 cys-diabody (A2cDb) targeting the cell-surface prostate stem cell antigen (PSCA), which is expressed in most pancreatic cancers.	a2 cys	52-58	prostate stem cell antigen	Mus musculus	130-134
32661830-0	2020	Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.	lu-dtpa	34-41	prostate stem cell antigen	Mus musculus	104-108
32355025-4	2020	Using single-cell RNA sequencing, we identified a rare luminal population in the mouse prostate that expresses stemlike genes (Sca1 + and Psca +) and a large population of differentiated cells (Nkx3.1 +, Pbsn +).	Phenobarbital	55-62	prostate stem cell antigen	Mus musculus	138-142
30180567-7	2018	The monoclonal anti-PSCA antibody 7F5 conjugates with thiocyanate BPC derivative or NODAGA were radiolabeled and studied in PC3-PSCA tumor bearing mice by PET.	thiocyanate	54-65	prostate stem cell antigen	Mus musculus	20-24
30180567-7	2018	The monoclonal anti-PSCA antibody 7F5 conjugates with thiocyanate BPC derivative or NODAGA were radiolabeled and studied in PC3-PSCA tumor bearing mice by PET.	bpc	66-69	prostate stem cell antigen	Mus musculus	20-24
29602820-3	2018	Methods: We developed a dual-labeled probe based on A2 cys-diabody (A2cDb) targeting the cell-surface prostate stem cell antigen (PSCA), which is expressed in most pancreatic cancers.	a2cdb	68-73	prostate stem cell antigen	Mus musculus	130-134
29602820-13	2018	Conclusion: Dual-modality imaging using the anti-PSCA cys-diabody resulted in high-contrast immuno-PET/NIRF images of PDX-PDACs, suggesting that this imaging agent might offer both noninvasive whole-body imaging to localize PSCA-positive pancreatic cancer and fluorescence image-guided identification of tumor margins during surgery.	Cysteine	54-57	prostate stem cell antigen	Mus musculus	49-53
29602820-13	2018	Conclusion: Dual-modality imaging using the anti-PSCA cys-diabody resulted in high-contrast immuno-PET/NIRF images of PDX-PDACs, suggesting that this imaging agent might offer both noninvasive whole-body imaging to localize PSCA-positive pancreatic cancer and fluorescence image-guided identification of tumor margins during surgery.	Cysteine	54-57	prostate stem cell antigen	Mus musculus	224-228
26490315-4	2016	EXPERIMENTAL DESIGN: An antibody fragment (cys-diabody, cDb) against prostate stem cell antigen (PSCA) was conjugated to a far-red fluorophore, Cy5.	Cysteine	43-46	prostate stem cell antigen	Mus musculus	97-101
26490315-4	2016	EXPERIMENTAL DESIGN: An antibody fragment (cys-diabody, cDb) against prostate stem cell antigen (PSCA) was conjugated to a far-red fluorophore, Cy5.	cdb	56-59	prostate stem cell antigen	Mus musculus	97-101
26490315-4	2016	EXPERIMENTAL DESIGN: An antibody fragment (cys-diabody, cDb) against prostate stem cell antigen (PSCA) was conjugated to a far-red fluorophore, Cy5.	cyanine dye 5	144-147	prostate stem cell antigen	Mus musculus	97-101
26490315-8	2016	RESULTS: Cy5-cDb demonstrated excellent purity, stability, and specific binding to PSCA.	cy5-cdb	9-16	prostate stem cell antigen	Mus musculus	83-87
24709520-1	2014	Multiwalled carbon nanotubes (MWCNTs) are cut short and grafted with polyethylenimine (PEI) for further covalent conjugation to fluorescein isothiocyanate (FITC) and prostate stem cell antigen (PSCA) monoclonal antibody (mAb).	Carbon	12-18	prostate stem cell antigen	Mus musculus	194-198
25326233-8	2014	LAPC-9 subcutaneous xenografts showed downregulation of PSCA when treated with MDV-3100 which A11 minibody immunoPET was able to detect in vivo.	lenampicillin	0-4	prostate stem cell antigen	Mus musculus	56-60
25399517-13	2015	CONCLUSION: Forced LIGHT treatment combined with PSCA TriVax therapeutic vaccination delays prostate cancer progression in mice by recruiting effector T lymphocytes to the tumor and inhibiting Treg mediated immunosuppression.	methfuroxam	54-60	prostate stem cell antigen	Mus musculus	49-53
24709520-1	2014	Multiwalled carbon nanotubes (MWCNTs) are cut short and grafted with polyethylenimine (PEI) for further covalent conjugation to fluorescein isothiocyanate (FITC) and prostate stem cell antigen (PSCA) monoclonal antibody (mAb).	Polyethyleneimine	69-85	prostate stem cell antigen	Mus musculus	194-198
24709520-1	2014	Multiwalled carbon nanotubes (MWCNTs) are cut short and grafted with polyethylenimine (PEI) for further covalent conjugation to fluorescein isothiocyanate (FITC) and prostate stem cell antigen (PSCA) monoclonal antibody (mAb).	Polyethyleneimine	87-90	prostate stem cell antigen	Mus musculus	194-198
24709520-3	2014	Combined flow cytometry and confocal luminescence imaging experiments confirm that the CNT-PEI(FITC)-mAb can specifically target the cancer cells which overexpress PSCA.	Fluorescein-5-isothiocyanate	95-99	prostate stem cell antigen	Mus musculus	164-168
20374648-8	2010	Mice bearing subcutaneous tumors showed a reduced tumor growth upon treatment with dox, which effectively induced shRNA against PSCA as revealed by GFP expression.	Doxycycline	83-86	prostate stem cell antigen	Mus musculus	128-132
23139820-7	2012	Taken together, these data suggest that DCLV is a potent vaccine carrier for PSCA in delivering anti-prostate cancer immunity.	dclv	40-44	prostate stem cell antigen	Mus musculus	77-81
19940180-5	2009	Misexpressing PSCA before cell death in the ciliary ganglion blocks alpha7-nAChR activation by nicotine and rescues the choroid subpopulation from dying.	Nicotine	95-103	prostate stem cell antigen	Mus musculus	14-18
16949054-8	2006	Increased psca promoter activity was also seen following treatment of cells with sulindac sulfone, another NSAID-like agent, but not with celecoxib treatment.	sulindac sulfone	81-97	prostate stem cell antigen	Mus musculus	10-14
12172427-4	2002	RECENT FINDINGS: PSCA is a glycosylphosphatidylinositol-anchored cell-surface protein belonging to the Ly-6/Thy-1 family of cell surface antigens, and a murine homologue has been described.	Glycosylphosphatidylinositols	27-55	prostate stem cell antigen	Mus musculus	17-21